乌帕替尼治疗特应性皮炎96周真实世界结局:系统治疗初治与经治患者比较
本研究为前瞻性真实世界研究,纳入327例日本中重度特应性皮炎患者,接受乌帕替尼15mg(n=248)或30mg(n=79)治疗。结果显示两种剂量在第4周均降低EASI、ADCT和峰值瘙痒NRS,且多数维持至第96周;但15mg经治患者在36周后临床评分轻度升高。
要点
- 乌帕替尼15mg和30mg在第4周快速改善EASI、ADCT及瘙痒NRS,并大多维持至96周。
- 系统治疗经治患者使用15mg时,36周后临床评分轻度升高。
- 总嗜酸性粒细胞计数在第4或12周急剧下降后平台,15mg经治患者36周后出现升高。
核心结论
- 乌帕替尼在96周真实世界实践中对特应性皮炎总体显示持续疗效,但15mg经治患者在36周后疗效轻度减弱。
研究设计与样本
- 前瞻性真实世界研究,纳入327例日本中重度特应性皮炎患者,接受乌帕替尼15mg(n=248)或30mg(n=79)治疗。
- 按既往是否接受系统治疗分层,评估临床和实验室指标至第96周。
主要发现
- 乌帕替尼15mg和30mg在第4周降低湿疹面积和严重度指数(EASI)、特应性皮炎控制工具(ADCT)和峰值瘙痒数值评定量表(NRS),且这些降低大多维持至第96周。
- 系统治疗经治患者使用15mg时,在第36周后的时间点临床评分轻度升高。
- 总嗜酸性粒细胞计数在第4或12周急剧下降后平台,例外为15mg经治患者在36周后出现升高。
临床怎么用
- 真实世界中长期使用乌帕替尼时,对系统治疗经治患者使用15mg需关注36周后疗效可能轻度减弱。
局限性
- 单中心研究,且仅限于日本人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term (2 years) effectiveness of upadacitinib for atopic dermatitis (AD) is unknown in real-world practice. OBJECTIVE: To evaluate 96-week real-world effectiveness of upadacitinib in Japanese patients with moderate-to-severe AD, stratified by the presence or absence of prior systemic therapies. METHODS: This prospective study included 327 Japanese patients treated with upadacitinib 15 mg (n = 248) or 30 mg (n = 79). Clinical and laboratory indexes were assessed until week 96 in systemic therapy-naive and -experienced patients. RESULTS: Upadacitinib 15 and 30 mg reduced eczema area and severity index, atopic dermatitis control tool, and peak pruritus numerical rating scale at week 4, and these reductions were mostly maintained until week 96. The clinical scores slightly increased at time points later than week 36 in systemic-therapy-experienced patients treated with 15 mg. Total eosinophil count sharply decreased at week 4 or 12 and plateaued thereafter except for the increase at time points later than week 36 in systemic therapy-experienced patients treated with 15 mg. LIMITATIONS: Single-center and Japanese-limited cohort. CONCLUSIONS: Upadacitinib demonstrated mostly sustained effectiveness for AD throughout a 96-week period in real-world practice with slightly reduced effectiveness at time points later than week 36 in systemic therapy-experienced patients treated with 15 mg upadacitinib.
引用
- Hagino T, Saeki H, Fujimoto E, et al. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients. J Am Acad Dermatol. 2025. PMID: 39880172. doi:10.1016/j.jaad.2025.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。